Literature DB >> 3942082

Usefulness of two-dimensional exercise echocardiography shortly after myocardial infarction.

W Jaarsma, C A Visser, A J Kupper, J C Res, M J van Eenige, J P Roos.   

Abstract

To determine the clinical significance of transient remote asynergy after the first acute myocardial infarction (AMI), 2-dimensional echocardiography was performed at rest and directly after dynamic exercise in 49 consecutive patients within 3 weeks of AMI. In 43 patients (88%), technically adequate 2-dimensional echocardiographic examinations were obtained. Asynergy was found in all patients at rest. Immediately after exercise, new areas of asynergy, not adjacent to the infarcted area (i.e., transient remote asynergy), were present in 18 patients. Of these patients, 17 had multivessel coronary artery disease (CAD), compared with 5 of 25 patients without transient remote asynergy. Sensitivity of transient remote asynergy for detecting multivessel CAD was 77% and specificity was 95%. Left ventricular ejection fraction at rest and after exercise was measured in 39 patients (90%) and could only identify patients with 3-vessel CAD. New ischemic events, defined as reinfarction or recurrent angina pectoris, within a mean of 12 weeks (range 8 to 16) after discharge, occurred in 16 patients. Transient remote asynergy was present in 12 of these patients (75%). It is concluded that exercise-induced transient remote asynergy early after AMI can identify patients with multivessel CAD and a subgroup of patients prone to early new ischemic events. Left ventricular ejection fraction, however, is not only more laborious but also of lesser value in identifying patients with multivessel CAD.

Entities:  

Mesh:

Year:  1986        PMID: 3942082     DOI: 10.1016/0002-9149(86)90957-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  10 in total

1.  Echocardiography in the assessment of complications of myocardial infarction.

Authors:  S Wilansky
Journal:  Tex Heart Inst J       Date:  1991

Review 2.  The role of stress echocardiography versus stress perfusion: a view from the other side.

Authors:  F A Chaudhry
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

Review 3.  Stress echocardiography: methods, indications and results.

Authors:  L H B Baur
Journal:  Neth Heart J       Date:  2002-03       Impact factor: 2.380

Review 4.  Comparison of approaches in the assessment of myocardial viability and follow-up of PTCA/CABG. The role of echocardiography.

Authors:  L A Piérard
Journal:  Int J Card Imaging       Date:  1993

5.  Prognostic assessment of uncomplicated first myocardial infarction by exercise echocardiography and Tc-99m tetrofosmin gated SPECT.

Authors:  J Candell-Riera; J Llevadot; C Santana; J Castell; S Aguadé; L Armadans; B Bermejo; G Oller; H García-del-Castillo; M Soler-Peter; J Soler-Soler
Journal:  J Nucl Cardiol       Date:  2001 Mar-Apr       Impact factor: 5.952

Review 6.  Echocardiography and coronary artery disease: current and future applications.

Authors:  W F Armstrong
Journal:  Int J Card Imaging       Date:  1987

Review 7.  A consideration of current clinical options for stress imaging in the diagnosis and evaluation of coronary artery disease.

Authors:  E H Botvinick
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

8.  The differing prognostic utility of exercise radionuclide ventriculography in coronary artery disease patients with and without prior myocardial infarction.

Authors:  M Moriel; A Rozanski; J Klein; D S Berman; C N Merz
Journal:  Int J Card Imaging       Date:  1997-10

Review 9.  Dobutamine stress echocardiography in clinical practice with a review of the recent literature.

Authors:  E Barasch; S Wilansky
Journal:  Tex Heart Inst J       Date:  1994

Review 10.  The clinical use of stress echocardiography in ischemic heart disease.

Authors:  Rosa Sicari; Lauro Cortigiani
Journal:  Cardiovasc Ultrasound       Date:  2017-03-21       Impact factor: 2.062

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.